risperidone has been researched along with Hallucination of Body Sensation in 73 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group." | 9.17 | Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. ( Hugdahl, K; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM; Sinkeviciute, I, 2013) |
| "Risperidone with routine clinical management was effective for the treatment of delirium: 48% of the patients responded and 38% achieved remission." | 9.16 | Treatment of delirium with risperidone in cancer patients. ( Kato, M; Kishi, Y; Okuyama, T; Thurber, S, 2012) |
| "An open-label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia." | 9.11 | An open study of risperidone liquid in the acute phase of schizophrenia. ( Egami, H; Goto, M; Kaji, K; Kakihara, S; Kohara, K; Maeda, H; Nakamura, J; Ninomiya, H; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2005) |
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 9.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| "The authors describe a series of 22 patients with dementia and behavioral disturbances, including agitation, aggression, delusions, and hallucinations, who were treated with risperidone." | 9.08 | Risperidone for the treatment of behavioral disturbances in dementia: a case series. ( Campbell, B; Flynn, M; Herrmann, N; Rabheru, K; Rivard, MF; Ward, C, 1998) |
| "Drug-induced delirium can occur with several drugs, including diphenhydramine." | 7.72 | Acute delirium associated with combined diphenhydramine and linezolid use. ( Serio, RN, 2004) |
| "We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects." | 7.72 | Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy. ( Buyse, GM; Proost, JE; Van Hove, JL; Vercammen, L, 2003) |
| " In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group." | 5.17 | Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. ( Hugdahl, K; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM; Sinkeviciute, I, 2013) |
| "Risperidone with routine clinical management was effective for the treatment of delirium: 48% of the patients responded and 38% achieved remission." | 5.16 | Treatment of delirium with risperidone in cancer patients. ( Kato, M; Kishi, Y; Okuyama, T; Thurber, S, 2012) |
| "To compare the efficacy of electro-acupuncture with that of sham electro-acupuncture for auditory hallucinations in patients with schizophrenia partially responsive or non-responsive to risperidone." | 5.14 | Electro-acupuncture versus sham electro-acupuncture for auditory hallucinations in patients with schizophrenia: a randomized controlled trial. ( , 2009) |
| "An open-label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia." | 5.11 | An open study of risperidone liquid in the acute phase of schizophrenia. ( Egami, H; Goto, M; Kaji, K; Kakihara, S; Kohara, K; Maeda, H; Nakamura, J; Ninomiya, H; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2005) |
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 5.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| "The authors describe a series of 22 patients with dementia and behavioral disturbances, including agitation, aggression, delusions, and hallucinations, who were treated with risperidone." | 5.08 | Risperidone for the treatment of behavioral disturbances in dementia: a case series. ( Campbell, B; Flynn, M; Herrmann, N; Rabheru, K; Rivard, MF; Ward, C, 1998) |
| " Withdrawal of the narcolepsy treatment and initiation of haloperidol 1 mg/day (the only antipsychotic treatment she could tolerate) improved the delusions, hallucinations and dysphoria but worsened the narcolepsy symptoms." | 3.85 | Narcolepsy-cataplexy and psychosis: a case study. ( Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R, 2017) |
| "Patients with severe baseline hallucinations were more likely to relapse after randomization, and the presence of baseline hallucinations was associated with a higher risk of relapse after discontinuation of risperidone compared with continued risperidone treatment." | 3.85 | Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations. ( Andrews, HF; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Lee, S; Levin, B; Mintzer, J; Patel, AN; Pelton, GH; Schimming, C; Schultz, SK; Sultzer, DL, 2017) |
| "We report a case of Sydenham's chorea with neuropsychiatric symptoms who was successfully treated with low-dose risperidone." | 3.75 | Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea. ( Hori, H; Korogi, Y; Nakamura, J; Nakano, H; Shimono, M; Shiota, N; Sugita, A; Takano, K; Tomoda, Y; Umene, W; Yoshimura, R, 2009) |
| "Nine neuroleptic-naive patients with first-episode schizophrenia (Diagnostic and Statistical Manual for Mental Disorders-IV criteria) with prominent AVH underwent three PET scans using F-fluordeoxyglucose (FDG): (i) shortly after presentation, while experiencing prominent and frequent AVH; (ii) after medication-induced remission (R), using a stable dose of risperidone; (iii) also in remission, during bilateral linguistic auditory activation (LAA) induced by spoken text mimicking the content of the hallucinations experienced while the first PET was performed, using headphones." | 3.74 | Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic-auditory activation. ( Bernardo, M; Fernández-Egea, E; Font, M; Gutierrez, F; Lomena, F; Parellada, E; Pareto, D; Pavia, J; Ros, D; Simo, M, 2008) |
| " His hallucinations and delusions remitted after treatment with risperidone, paralleling motor improvement." | 3.74 | Psychosis following acute Sydenham's chorea. ( Cardoso, F; Maia, DP; Teixeira, AL, 2007) |
| " Auditory hallucinations had developed 25 years previously, for which haloperidol had been prescribed." | 3.74 | Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam. ( Inada, T; Oda, T; Yamamoto, N, 2007) |
| "Drug-induced delirium can occur with several drugs, including diphenhydramine." | 3.72 | Acute delirium associated with combined diphenhydramine and linezolid use. ( Serio, RN, 2004) |
| " We present a case of post-traumatic delirium with delusions treated with Risperidone and discuss the use of AAP's in this situation." | 3.72 | Use of atypical anti-psychotics in the management of post-traumatic confusional states in traumatic brain injury. ( Temple, MJ, 2003) |
| "We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects." | 3.72 | Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy. ( Buyse, GM; Proost, JE; Van Hove, JL; Vercammen, L, 2003) |
| "Risperidone, a novel neuroleptic with approximately equal D2 and 5HT2A receptor blocking properties, has been used to treat drug-related hallucinations in patients with Parkinson's disease." | 3.70 | Risperidone treatment of drug-related psychosis in patients with parkinsonism. ( Leopold, NA, 2000) |
| "A significant improvement was found in auditory hallucinations in the experimental group as compared to the control group." | 2.74 | Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. ( Bagati, D; Nizamie, SH; Prakash, R, 2009) |
| "Hallucinations and psychosis are common in patients with Parkinson's disease (PD), with reported prevalences of up to 48% and 80%, respectively." | 2.46 | Management of hallucinations and psychosis in Parkinson's disease. ( Eng, ML; Welty, TE, 2010) |
| "Turner syndrome encompasses several chromosomal abnormalities and includes a typical clinical manifestation." | 2.45 | [Turner-syndrome and psychosis: a case report and brief review of the literature]. ( Preuss, UW; Wustmann, T, 2009) |
| "Significant consequences of untreated psychosis in patients with dementia have led clinicians to seek improved therapeutic options." | 2.40 | Pharmacologic management of psychosis in dementia. ( Schneider, LS, 1999) |
| "Schizophrenia is a psychiatric disorder that presents with hallucinations, delusions, thought disorders, and cognitive dysfunctions." | 1.91 | [Antipsychotics]. ( Hashimoto, R; Yamada, H, 2023) |
| "Narcolepsy is characterized by symptoms that include excessive sleepiness during the daytime, cataplexy, hypnagogic hallucinations and sleep paralysis." | 1.35 | Narcolepsy and psychotic states--a case report. ( Daliahu, Y; Melamed, Y; Paleacu, D, 2009) |
| "Psychogenic non-epileptic seizures can co-exist with epileptic seizures." | 1.34 | Development of psychogenic non-epileptic seizures in response to auditory hallucinations. ( Devine, MJ; Duncan, JS, 2007) |
| "Though it was difficult to control their visual hallucinations with medication only, cataract surgery made them disappeared quickly." | 1.32 | [Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery]. ( Kameyama, M; Kubori, T; Matsui, H; Nishinaka, K; Oda, M; Udaka, F, 2004) |
| " Clinicians should attempt to treat patients with the lowest effective dosage of medication for the briefest therapeutic period to minimize the risks of adverse reactions." | 1.31 | Metoclopramide-induced supersensitivity psychosis. ( Lu, ML; Pan, JJ; Shen, WW; Su, KP; Teng, HW, 2002) |
| "Risperidone was an effective and safe treatment in three cases of delusions of infestation." | 1.30 | Risperidone in the treatment of delusions of infestation. ( Bailey, LG; Canterbury, AL; De León, OA; Furmaga, KM, 1997) |
| "PTSD is a possible sequela of exposure to traumatic events." | 1.30 | Risperidone as an adjunct therapy for post-traumatic stress disorder. ( Krashin, D; Oates, EW, 1999) |
| "When treated with clomipramine 100 mg daily (plasma level 85 ng/mL), obsessive-compulsive symptoms but not the hallucinations improved significantly, and racing thoughts and grandiosity developed later." | 1.29 | Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. ( Dryden-Edwards, RC; Reiss, AL, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (16.44) | 18.2507 |
| 2000's | 40 (54.79) | 29.6817 |
| 2010's | 18 (24.66) | 24.3611 |
| 2020's | 3 (4.11) | 2.80 |
| Authors | Studies |
|---|---|
| Yamada, H | 1 |
| Hashimoto, R | 1 |
| Rojo-Moreno, J | 1 |
| Rojo-Valdemoro, C | 1 |
| Santolaya-Ochando, F | 1 |
| Lin, X | 1 |
| Li, G | 1 |
| Ji, F | 1 |
| Cheng, L | 1 |
| Chen, G | 1 |
| Zhang, W | 1 |
| Su, Z | 1 |
| Zhang, Z | 1 |
| Wang, W | 1 |
| Zhou, C | 1 |
| Xu, Y | 1 |
| Zhuo, C | 1 |
| Spiegel, DR | 3 |
| Harsch, C | 1 |
| Pattison, A | 1 |
| Lavretsky, H | 1 |
| Canellas-Dols, F | 1 |
| Delgado, C | 1 |
| Arango-Lopez, C | 1 |
| Peraita-Adrados, R | 1 |
| Koh, MT | 1 |
| Ahrens, PS | 1 |
| Gallagher, M | 1 |
| Thusius, N | 1 |
| Romanowicz, M | 1 |
| Mlynek, K | 1 |
| Sola, C | 1 |
| Johnsen, E | 1 |
| Sinkeviciute, I | 1 |
| Løberg, EM | 1 |
| Kroken, RA | 1 |
| Hugdahl, K | 1 |
| Jørgensen, HA | 1 |
| Birkeland, SF | 1 |
| Michael, S | 1 |
| Boulton, M | 1 |
| Andrews, G | 1 |
| Rivers, J | 1 |
| Peglow, S | 1 |
| Kamijo, Y | 1 |
| Colombel, M | 1 |
| Rebillard, C | 1 |
| Nathou, C | 1 |
| Dollfus, S | 1 |
| Patel, AN | 1 |
| Lee, S | 1 |
| Andrews, HF | 1 |
| Pelton, GH | 1 |
| Schultz, SK | 1 |
| Sultzer, DL | 1 |
| Mintzer, J | 1 |
| de la Pena, D | 1 |
| Gupta, S | 1 |
| Colon, S | 1 |
| Schimming, C | 1 |
| Levin, B | 1 |
| Devanand, DP | 1 |
| Thomas Antérion, C | 1 |
| Convers, P | 1 |
| Desmales, S | 1 |
| Borg, C | 1 |
| Laurent, B | 1 |
| Bharadwaj, R | 1 |
| Grover, S | 1 |
| Parellada, E | 1 |
| Lomena, F | 1 |
| Font, M | 1 |
| Pareto, D | 1 |
| Gutierrez, F | 1 |
| Simo, M | 1 |
| Fernández-Egea, E | 1 |
| Pavia, J | 1 |
| Ros, D | 1 |
| Bernardo, M | 1 |
| Wustmann, T | 1 |
| Preuss, UW | 1 |
| Campbell, JJ | 1 |
| Ngo, G | 1 |
| Bagati, D | 2 |
| Nizamie, SH | 1 |
| Prakash, R | 1 |
| Praharaj, SK | 1 |
| Goyal, N | 1 |
| Sarkar, S | 1 |
| Sinha, P | 1 |
| Sinha, VK | 1 |
| Melamed, Y | 1 |
| Daliahu, Y | 1 |
| Paleacu, D | 1 |
| Eng, ML | 1 |
| Welty, TE | 1 |
| Makkos, Z | 1 |
| Fejes, L | 1 |
| Inczédy-Farkas, G | 1 |
| Kassai-Farkas, A | 1 |
| Faludi, G | 1 |
| Lazáry, J | 1 |
| Petersen, T | 1 |
| Salinas Botrán, A | 1 |
| Urgelés Puértolas, D | 1 |
| Peregrin Abad, E | 1 |
| Kishi, Y | 1 |
| Kato, M | 1 |
| Okuyama, T | 1 |
| Thurber, S | 1 |
| Bozkurt, H | 1 |
| Ayaydın, H | 1 |
| Adak, İ | 1 |
| Zoroğlu, SS | 1 |
| Lu, ML | 1 |
| Pan, JJ | 1 |
| Teng, HW | 1 |
| Su, KP | 1 |
| Shen, WW | 1 |
| Friedman, JH | 1 |
| Fernandez, HH | 1 |
| Livingston, M | 1 |
| Livingston, H | 1 |
| Temple, MJ | 1 |
| Vercammen, L | 1 |
| Buyse, GM | 1 |
| Proost, JE | 1 |
| Van Hove, JL | 1 |
| Ikeda, H | 1 |
| Yamamoto, M | 1 |
| Hashimoto, E | 1 |
| Saito, T | 1 |
| Maeda, K | 1 |
| Shirayama, Y | 1 |
| Nukina, S | 1 |
| Yoshioka, S | 1 |
| Kawahara, R | 1 |
| Serio, RN | 1 |
| Weiner, SK | 1 |
| Sluys, M | 1 |
| Güzelcan, Y | 1 |
| Casteelen, G | 1 |
| de Haan, L | 1 |
| Matsui, H | 1 |
| Udaka, F | 1 |
| Oda, M | 1 |
| Kubori, T | 1 |
| Nishinaka, K | 1 |
| Kameyama, M | 1 |
| Heveling, T | 1 |
| Emrich, HM | 1 |
| Dietrich, DE | 1 |
| Eren, I | 1 |
| Ozcankaya, R | 1 |
| Altinyazar, V | 1 |
| Mulsant, BH | 1 |
| Gharabawi, GM | 1 |
| Bossie, CA | 1 |
| Mao, L | 1 |
| Martinez, RA | 1 |
| Tune, LE | 1 |
| Greenspan, AJ | 1 |
| Bastean, JN | 1 |
| Pollock, BG | 1 |
| Yoshimura, R | 2 |
| Nakamura, J | 2 |
| Shinkai, K | 1 |
| Goto, M | 1 |
| Yamada, Y | 1 |
| Kaji, K | 1 |
| Kakihara, S | 1 |
| Ueda, N | 1 |
| Kohara, K | 1 |
| Ninomiya, H | 1 |
| Egami, H | 1 |
| Maeda, H | 1 |
| Duggal, HS | 1 |
| Reiss, JP | 1 |
| Sam, D | 1 |
| Sareen, J | 1 |
| Johnson, J | 1 |
| Bourgeois, JA | 1 |
| Quanbeck, C | 1 |
| Guaiana, G | 1 |
| Markova, I | 1 |
| Teixeira, AL | 1 |
| Maia, DP | 1 |
| Cardoso, F | 1 |
| Fischer, RB | 1 |
| Devine, MJ | 1 |
| Duncan, JS | 1 |
| Umene, W | 1 |
| Hori, H | 1 |
| Nakano, H | 1 |
| Sugita, A | 1 |
| Shimono, M | 1 |
| Takano, K | 1 |
| Shiota, N | 1 |
| Tomoda, Y | 1 |
| Korogi, Y | 1 |
| Yamamoto, N | 1 |
| Oda, T | 1 |
| Inada, T | 1 |
| Kessler, H | 1 |
| Kraft, S | 1 |
| Meco, G | 1 |
| Alessandria, A | 1 |
| Bonifati, V | 1 |
| Giustini, P | 1 |
| Howard, R | 1 |
| Williams, S | 1 |
| Bullmore, E | 1 |
| Brammer, M | 1 |
| Mellers, J | 1 |
| Woodruff, P | 1 |
| David, A | 1 |
| Abraham, HD | 1 |
| Mamen, A | 1 |
| Lübbe, R | 1 |
| Dryden-Edwards, RC | 1 |
| Reiss, AL | 1 |
| De León, OA | 1 |
| Furmaga, KM | 1 |
| Canterbury, AL | 1 |
| Bailey, LG | 1 |
| Herrmann, N | 1 |
| Rivard, MF | 1 |
| Flynn, M | 1 |
| Ward, C | 1 |
| Rabheru, K | 1 |
| Campbell, B | 1 |
| Alcántara, AG | 1 |
| Schneider, LS | 1 |
| Krashin, D | 1 |
| Oates, EW | 1 |
| Snoddgrass, PL | 1 |
| Labbate, LA | 1 |
| Leopold, NA | 1 |
| Kornreich, C | 1 |
| Dan, B | 1 |
| Verbanck, P | 1 |
| Pelc, I | 1 |
| Solhkhah, R | 1 |
| Finkel, J | 1 |
| Hird, S | 1 |
| Jensen, HM | 1 |
| Poulsen, HD | 1 |
| Bahk, WM | 1 |
| Pae, CU | 1 |
| Chae, JH | 1 |
| Jun, TY | 1 |
| Kim, KS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.[NCT00932529] | Phase 4 | 226 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Antipsychotic Discontinuation in Alzheimer's Disease[NCT00417482] | Phase 4 | 180 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Abnormal Involuntary Movement Scale (AIMS) assesses signs of tardive dyskinesia, a movement disorder that can occur with prolonged use of antipsychotic medication. The AIMS score ranges from 0 to 35, with higher scores indicating more severe symptoms. For each subject, the change in AIMS score between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in AIMS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.03 |
| Risperidone | 0.24 |
Extrapyramidal signs, also known as Parkinsonian signs, refer to signs of tremor, rigidity, and bradykinesia (slowed movement) that are seen in Parkinson's disease. Assessment of extrapyramidal signs (EPS) were made with the use of the Simpson-Angus scale (which ranges from 1-40) with higher scores indicating more extrapyramidal signs. For each subject, the change in EPS between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in EPS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.20 |
| Risperidone | 0.34 |
The MMSE assesses cognition. Scores range from 0-30, with higher scores indicating better cognition. For each subject, the change in MMSE between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in MMSE over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.13 |
| Risperidone | -0.77 |
Physical Self-Maintenance Scale, which ranges from 1 to 30, with higher scores indicating WORSE functioning. For each subject, the change in PSMS between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in PSMS (worse functioning) over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.18 |
| Risperidone | 0.80 |
"A relapse occurred in Phase B (post-randomization) if both of the following criteria were met:~Increase in the Neuropsychiatric Inventory (NPI) core score of 30% or more OR a 5-point increase from the baseline NPI score at the end of Phase A~A score of 6 (much worse) or 7 (very much worse) on the Clinical Global Impression-Change (CGI-C) at any visit." (NCT00417482)
Timeframe: 0-16 weeks in Phase B (16-32 weeks in study)
| Intervention | participants (Number) |
|---|---|
| Phase B Arm 1: Risperidone-Risperidone | 15 |
| Phase B Arm 2: Risperidone -Placebo | 8 |
| Phase B Arm 3: Placebo-Placebo | 24 |
Same definition and criteria as the primary outcome (NCT00417482)
Timeframe: 16-32 weeks in Phase B (32-48 weeks in study)
| Intervention | participants (Number) |
|---|---|
| Arm 1: Risperidone - Risperidone | 2 |
| Arm 2: Risperidone - Placebo | 13 |
The Treatment Emergent Symptom Scale (TESS) assesses 26 somatic symptoms. Total scores range from 0-26, with a score of 0 or 1 for each item. Higher scores indicate more somatic symptoms. For each subject, the change in TESS between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in TESS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.18 |
| Risperidone | 0.21 |
For each subject, the change in weight in pounds between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in weight over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | pounds (Mean) |
|---|---|
| Placebo | 0.32 |
| Risperidone | 0.73 |
9 reviews available for risperidone and Hallucination of Body Sensation
| Article | Year |
|---|---|
[Dangerous drugs: products containing synthetic chemicals].
Topics: Alkaloids; Antipsychotic Agents; Cannabinoids; Central Nervous System Diseases; Consciousness Disord | 2016 |
[Turner-syndrome and psychosis: a case report and brief review of the literature].
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Chromosome Aberrati | 2009 |
Management of hallucinations and psychosis in Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Comorbidity; Delusions; Demen | 2010 |
Atypical antipsychotics in Parkinson-sensitive populations.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia, Vascular; Dibenzothia | 2002 |
Using antipsychotics in elderly patients.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Delusions; Hallucinations; Humans; Olanzapine; Pirenzep | 2002 |
[Alcohol hallucinosis].
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Dopamine; Hallucinations | 2003 |
[Neuropsychiatric symptoms in Sotos syndrome. Case report and review of the literature].
Topics: Adult; Antipsychotic Agents; Brain; Carbamazepine; Chromosome Deletion; Citalopram; Compulsive Behav | 2008 |
Assessing the effects of atypical antipsychotics on negative symptoms. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Delusions; Depressive Disorder; Hallucinati | 1998 |
Pharmacologic management of psychosis in dementia.
Topics: Aged; Antipsychotic Agents; Clozapine; Comorbidity; Delusions; Dementia; Hallucinations; Humans; Psy | 1999 |
7 trials available for risperidone and Hallucination of Body Sensation
| Article | Year |
|---|---|
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Hallucinations; Hospitaliz | 2013 |
Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study.
Topics: Adult; Antipsychotic Agents; Female; Hallucinations; Haloperidol; Humans; International Classificati | 2009 |
Electro-acupuncture versus sham electro-acupuncture for auditory hallucinations in patients with schizophrenia: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Drug Resistance; Electroacupuncture; Female; Hallucinations; Humans; Ma | 2009 |
Treatment of delirium with risperidone in cancer patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Hallucinations; Humans; Male; Middl | 2012 |
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorders; Delusions; Demen | 2004 |
An open study of risperidone liquid in the acute phase of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Chromatography, High Pressure Liquid; | 2005 |
Risperidone for the treatment of behavioral disturbances in dementia: a case series.
Topics: Aged; Aged, 80 and over; Aggression; Antipsychotic Agents; Behavioral Symptoms; Delusions; Dementia; | 1998 |
57 other studies available for risperidone and Hallucination of Body Sensation
| Article | Year |
|---|---|
[Antipsychotics].
Topics: Antipsychotic Agents; Clozapine; Hallucinations; Humans; Risperidone; Schizophrenia | 2023 |
Royal Eschizophilia. Genealogical delusion or Mignon delusion as a pathoplastic realization.
Topics: Age Factors; Antipsychotic Agents; Carbamazepine; Delusions; Disease Progression; Fellowships and Sc | 2019 |
A typical antipsychotic treatment induced gradually expanding white matter alterations in healthy individuals with persistent auditory verbal hallucinations-an artificially controlled pilot study.
Topics: Adult; Antipsychotic Agents; Corpus Callosum; Diffusion Tensor Imaging; Female; Hallucinations; Huma | 2021 |
A Case of Peduncular Hallucinosis Due to Right Pontine and Cerebral Peduncle Cerebrovascular Accident Treated Successfully With Risperidone: Insights Into an Uncommon Cause of Visual Hallucinations.
Topics: Cerebral Peduncle; Hallucinations; Humans; Risperidone; Stroke | 2020 |
Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation.
Topics: Alzheimer Disease; Antipsychotic Agents; Hallucinations; Humans; Psychomotor Agitation; Psychotic Di | 2017 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
A greater tendency for representation mediated learning in a ketamine mouse model of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Delusions; Disease Mo | 2018 |
Prolonged Psychosis Associated with Left Insular Stroke: Talking to God in the Walls.
Topics: Aged; Antimanic Agents; Antipsychotic Agents; Cerebral Cortex; Electroencephalography; Hallucination | 2018 |
Paranoid personality disorder and the schizophrenia spectrum-Where to draw the line?
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Diagnosis, Differential; Diagnostic and Statistical Ma | 2013 |
Two cases of olfactory reference syndrome responding to an atypical antipsychotic and SSRI.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Citalopram; Delusions; Drug Therapy, Combination; Female; | 2014 |
A probable case of peduncular hallucinosis status postthalamic and cerebral peduncle cerebrovascular accident treated successfully with risperidone.
Topics: Adult; Antipsychotic Agents; Brain Stem; Cerebral Peduncle; Female; Hallucinations; Humans; Risperid | 2014 |
[Can men be included in the population subjected to puerperal psychosis? A case report].
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Delusions; Denial, Psychological; | 2016 |
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Female; Hallucinations; Humans; Intention to Treat An | 2017 |
An odd manifestation of the Capgras syndrome: loss of familiarity even with the sexual partner.
Topics: Aged; Amnesia; Antipsychotic Agents; Atrophy; Brain; Capgras Syndrome; Donepezil; Hallucinations; Hu | 2008 |
Parkinsonism and akathisia with quetiapine: three case reports.
Topics: Adolescent; Antipsychotic Agents; Dibenzothiazepines; Female; Hallucinations; Humans; Parkinsonian D | 2008 |
Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic-auditory activation.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Brain Mapping; Female; Fluorodeoxyglucose F18; Ha | 2008 |
Risperidone treatment of complex hallucinations in a patient with posterior cortical atrophy.
Topics: Atrophy; Brain Diseases; Cerebral Cortex; Dopamine Antagonists; Hallucinations; Risperidone | 2008 |
Musical obsession or pseudohallucination: electrophysiological standpoint.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Drug Therapy, Combination; Electroen | 2009 |
Narcolepsy and psychotic states--a case report.
Topics: Antipsychotic Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Comorbidit | 2009 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diben | 2011 |
Complex visual hallucinations, presumably due to subarachnoid hemorrhage, treated successfully with risperidone.
Topics: Dopamine Antagonists; Female; Hallucinations; Humans; Middle Aged; Risperidone; Subarachnoid Hemorrh | 2011 |
[Postpartum psychosis associated with cabergoline].
Topics: Adult; Antipsychotic Agents; Cabergoline; Cesarean Section; Dopamine Agonists; Ergolines; Female; Ha | 2013 |
Risperidone-induced paroxysmal perceptual alteration in a child with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Hallucinations; Humans; Male; Perceptual Disorders; | 2012 |
Metoclopramide-induced supersensitivity psychosis.
Topics: Aged; Antiemetics; Antipsychotic Agents; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Hallucina | 2002 |
Use of atypical anti-psychotics in the management of post-traumatic confusional states in traumatic brain injury.
Topics: Antipsychotic Agents; Brain Injuries; Delirium; Hallucinations; Humans; Male; Middle Aged; Risperido | 2003 |
Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy.
Topics: Adult; Antipsychotic Agents; Creatine Kinase; Dopamine; Female; Fever; Hallucinations; Humans; Intel | 2003 |
Charles Bonnet syndrome with visual hallucinations of childhood experience: successful treatment of 1 patient with risperidone.
Topics: Antipsychotic Agents; Cataract Extraction; Child; Diabetic Retinopathy; Female; Hallucinations; Huma | 2003 |
Acute delirium associated with combined diphenhydramine and linezolid use.
Topics: Acetamides; Acute Disease; Delirium; Diphenhydramine; Drug Combinations; Drug Interactions; Duty to | 2004 |
First person account: living with the delusions and effects of schizophrenia.
Topics: Adult; Antipsychotic Agents; Autobiographies as Topic; Delusions; Female; Hallucinations; Humans; Qu | 2003 |
Risperidone-induced leucopenia and neutropenia: a case report.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delusions; Dementia, Vascular; Hallucinations; Halope | 2004 |
[Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery].
Topics: Aged; Antiparkinson Agents; Bromocriptine; Cataract Extraction; Female; Hallucinations; Humans; Levo | 2004 |
Treatment of a rare psychopathological phenomenon: tactile hallucinations and the delusional other.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Chronic Disease; Delusions; Drug Therapy | 2004 |
Risperidone-induced rabbit syndrome in mood disorder.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Diagnosis, Differential; Hallucinations; Humans; M | 2004 |
Cognitive affective psychosis syndrome in a patient with sporadic olivopontocerebellar atrophy.
Topics: Adolescent; Affective Disorders, Psychotic; Anti-Dyskinesia Agents; Antidepressive Agents, Second-Ge | 2005 |
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delusions; Excitatory Amino Acid Antagonists; Female; | 2006 |
Treatment of olfactory hallucinations with topiramate.
Topics: Adult; Antipsychotic Agents; Fructose; Hallucinations; Humans; Male; Neuroprotective Agents; Prisons | 2006 |
Antipsychotic treatment improves outcome in herpes simplex encephalitis: a case report.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Comorbidity; Delusions; Encephalitis, Herpes Simpl | 2006 |
Psychosis following acute Sydenham's chorea.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Chorea; Fear; Hallucinations; Humans; Male; Mitral | 2007 |
Injectable sustained-release risperidone: recurrence of delirium and treatment failure.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Delirium; France; Hallucinations; Humans; Injecti | 2006 |
[Psychiatric illness associated with amphetamines and other stimulants].
Topics: Adult; Amnesia; Amphetamines; Central Nervous System Stimulants; Cognition Disorders; Designer Drugs | 2000 |
Development of psychogenic non-epileptic seizures in response to auditory hallucinations.
Topics: Adult; Antipsychotic Agents; Epilepsy; Hallucinations; Humans; Male; Risperidone; Seizures | 2007 |
Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea.
Topics: Adolescent; Antipsychotic Agents; Anxiety; Basal Ganglia; Brain-Derived Neurotrophic Factor; Catecho | 2009 |
Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.
Topics: Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Biperiden; Central Nervous Syst | 2007 |
Risperidone for hallucinations in levodopa-treated Parkinson's disease patients.
Topics: Aged; Antipsychotic Agents; Hallucinations; Humans; Isoxazoles; Levodopa; Parkinson Disease; Piperid | 1994 |
Cortical response to exogenous visual stimulation during visual hallucinations.
Topics: Aged; Antipsychotic Agents; Dementia; Evoked Potentials, Visual; Hallucinations; Humans; Isoxazoles; | 1995 |
LSD-like panic from risperidone in post-LSD visual disorder.
Topics: Adult; Antipsychotic Agents; Female; Hallucinations; Humans; Lysergic Acid Diethylamide; Male; Panic | 1996 |
[Remission of schizophrenic psychosis with negative symptoms with risperidone].
Topics: Adult; Antipsychotic Agents; Combined Modality Therapy; Depression; Hallucinations; Humans; Male; Ps | 1996 |
Differential response of psychotic and obsessive symptoms to risperidone in an adolescent.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Antipsychotic Agents; Clomipramine; Hallucinatio | 1996 |
Risperidone in the treatment of delusions of infestation.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delusions; Dementia; Ectoparasitic Infestation | 1997 |
Is there a role for the alpha2 antagonism in the exacerbation of hallucinogen-persisting perception disorder with risperidone?
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Antipsychotic Agents; Hallucinations; Humans; Perc | 1998 |
Risperidone as an adjunct therapy for post-traumatic stress disorder.
Topics: Adult; Antipsychotic Agents; Arousal; Delusions; Female; Hallucinations; Humans; Military Personnel; | 1999 |
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Dyskinesia, Drug-Induc | 1999 |
Risperidone treatment of drug-related psychosis in patients with parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Female; Hallucinations; Humans; | 2000 |
Treating Charles Bonnet syndrome: understanding inconsistency.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Hallucinations; Haloperidol; Humans; Male; Psychotic | 2000 |
Possible risperidone-induced visual hallucinations.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnosis, Du | 2000 |
Auto-vampirism in schizophrenia.
Topics: Adult; Antipsychotic Agents; Delusions; Depersonalization; Female; Hallucinations; Humans; Risperido | 2002 |
A case of brief psychosis associated with an arachnoid cyst.
Topics: Antipsychotic Agents; Arachnoid Cysts; Hallucinations; Headache; Humans; Magnetic Resonance Imaging; | 2002 |